- The FDA approves AstraZeneca (AZN +0.3%) and Bristol-Myers Squibb's (BMY +1.2%) Farxiga (dapaglifozin).
- The drug is intended to improve glycemic control in adults with Type 2 diabetes.
- Farxiga isn't recommended for patients with active bladder cancer and the regulator is "requiring six post-marketing studies," including a CVOT.
- FDA PR
at Zacks.com (Nov 18, 2014)